Top Markets
#1 Resolv wstUSR Resolv wstUSR +114.62%
#2 Luxxcoin Luxxcoin +45.27%
#3 ResearchCoin ResearchCoin +22.78%
#4 Reactive Network Reactive Network +20.67%
#5 Orderly Network Orderly Network +16.77%
#6 Layer3 Layer3 +13.71%
#7 Bitgert Bitgert +13.08%
#8 Aria.AI Aria.AI +11.86%
#9 Useless Coin Useless Coin +9.66%
#10 Lisk Bridged wstETH (Lisk) Lisk Bridged wstETH (Lisk) +9.53%
Coin of the day
Resolv wstUSR Resolv wstUSR
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
CSL Limited CSL Limited

CSL Limited

CSL
Classifica tra le azioni #432
CSL Limited researches, develops, manufactures, markets, and distributes... CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Prezzo delle azioni
$99.32
Capitalizzazione di mercato
$48.20B
Variazione (1 giorno)
0.98%
Variazione (1 anno)
-32.14%
Paese
AU
Scambia CSL Limited (CSL)

Categoria

Healthcare
Rapporto P/B per CSL Limited (CSL)
Rapporto P/B al April 2026 TTM: 2.55
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di CSL Limited, il rapporto P/B attuale (TTM) è 2.55. Alla fine del 2024, era pari a 5.43.
Storico del rapporto P/B per CSL Limited da 2000 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
2026 (TTM) 2.55 -35.36%
2025 3.94 -27.38%
2024 5.43 44.67%
2023 3.75 -8.59%
2022 4.11 -64.62%
2021 11.60 -41.84%
2020 19.95 52.81%
2019 13.06 -17.71%
2018 15.87 -20.12%
2017 19.87 32.34%
2016 15.01 -0.22%
2015 15.04 47.75%
2014 10.18 1.25%
2013 10.06 70.32%
2012 5.91 28.39%
2011 4.60 -10.55%
2010 5.14 17.45%
2009 4.38 -40.16%
2008 7.31 -12.44%
2007 8.35 25.21%
2006 6.67 58.64%
2005 4.21 53.56%
2004 2.74 23.37%
2003 2.22 -67.73%
2002 6.88 -56.70%
2001 15.89 71.69%
2000 9.25 0.00%
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 5.2875 107.61%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.074 138.50%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 2.5436 -0.13%
US
UCB SA UCB SA
UCB SA
UCB.BR
 4.5196 77.46%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.0209 136.41%
NL